Literature DB >> 28811008

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients.

Ching-I Huang1, Chung-Feng Huang2, Ming-Lun Yeh2, Yi-Hung Lin3, Po-Cheng Liang3, Meng-Hsuan Hsieh4, Chia-Yen Dai5, Ming-Yen Hsieh6, Zu-Yau Lin2, Shinn-Cherng Chen2, Jee-Fu Huang7, Ming-Lung Yu8, Wan-Long Chuang8.   

Abstract

Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP) has recently been developed as a promising liver fibrosis glyco biomarker. We assessed its efficacy in evaluating liver disease severity in chronic hepatitis C (CHC) in Taiwan. The association between WFA+-M2BP and histological features was evaluated among those CHC patients underwent liver biopsy. We also aimed to clarify the factors determining the performance of WFA+-M2BP in CHC. A total of 229 CHC patients were consecutively recruited. The mean value of WFA+-M2BP in patients from F0 to F4 was 1.68, 2.23, 3.45, 3.48, 3.77 respectively (linear trend P = 0.008). Linear regression analysis revealed that alanine aminotransferase (odds ratio [OR]: 0.03, 95% confidence intervals [CI]: 0.02-0.05, P < 0.001), AST (OR: -0.1, 95% CI: -0.02 to -0.01, P < 0.001), and liver fibrosis (OR: 0.30, 95% CI: 0.01-0.59, P = 0.043) were the independent factors correlated to serum WFA+-M2BP level. The optimal cutoff values of WFA+-M2BP for fibrosis stages F1, F2, F3, and F4 were 1.42, 1.61, 1.42, and 2.67, respectively. Multivariate analysis revealed that the platelet count (OR/CI: -0.009/0.986-0.996, P = <0.001), r-glutamyl transferase (OR/CI: 0.007/1.000-1.013, P = 0.036), and WFA+-M2BP (OR/CI: 0.187/1.057-1.374, P = 0.005). We concluded that WFA+-M2BP is a competent noninvasive marker for liver fibrosis assessment in CHC patients.
Copyright © 2017. Published by Elsevier Taiwan.

Entities:  

Keywords:  Hepatitis C virus; Liver fibrosis; M2BP

Mesh:

Substances:

Year:  2017        PMID: 28811008     DOI: 10.1016/j.kjms.2017.05.017

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  4 in total

1.  M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.

Authors:  Shereen A Saleh; Mohamed M Salama; Marwan M Alhusseini; Ghada A Mohamed
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

Review 2.  Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases.

Authors:  Nobuharu Tamaki; Masayuki Kurosaki; Rohit Loomba; Namiki Izumi
Journal:  Ann Lab Med       Date:  2020-08-25       Impact factor: 3.464

3.  Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis.

Authors:  Shu Feng; Zhonghao Wang; Yanhua Zhao; Chuanmin Tao
Journal:  Sci Rep       Date:  2020-06-29       Impact factor: 4.379

4.  Biomarker discovery for chronic liver diseases by multi-omics - a preclinical case study.

Authors:  Daniel Veyel; Kathrin Wenger; Andre Broermann; Tom Bretschneider; Andreas H Luippold; Bartlomiej Krawczyk; Wolfgang Rist; Eric Simon
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.